Enochian Biosciences, Inc.
ENOB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $3 | $4,165,197 | $8 |
| G&A Expenses | $18 | $25 | $15,318,198 | $14 |
| SG&A Expenses | $18 | $25 | $15,318,198 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $171 | $54 | $19,073,496 | $0 |
| Operating Expenses | $189 | $82 | $38,556,891 | $23 |
| Operating Income | -$189 | -$82 | -$38,556,891 | -$116 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $11 | $1 | -$1,127,165 | -$90 |
| Pre-Tax Income | -$178 | -$81 | -$39,684,056 | -$113 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$178 | -$81 | -$39,684,056 | -$113 |
| % Margin | – | – | – | – |
| EPS | -1.08 | -0.84 | -705,301.71 | -2.16 |
| % Growth | -28.6% | 100% | -32,652,756.9% | – |
| EPS Diluted | -1.08 | -0.84 | -705,301.71 | -2.16 |
| Weighted Avg Shares Out | 165 | 96 | 56 | 53 |
| Weighted Avg Shares Out Dil | 165 | 96 | 56 | 53 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | -$1 | -$580,344 | $0 |
| Depreciation & Amortization | $0 | $0 | $113,496 | $123,590 |
| EBITDA | -$177 | -$82 | -$40,150,904 | -$113,682,680 |
| % Margin | – | – | – | – |